EDITORIAL

A disruptive sequencer meets disruptive publishing [version 1; peer review: not peer reviewed]

Nick Loman¹, Sarah Goodwin², Hans J. Jansen³, Matt Loose⁴

¹Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
²Cold Spring Harbor Laboratory, Cold Harbour, NY, USA
³ZF-screens B.V., Leiden, The Netherlands
⁴University of Nottingham, Nottingham, UK

Abstract
Nanopore sequencing was recently made available to users in the form of the Oxford Nanopore MinION. Released to users through an early access programme, the MinION is made unique by its tiny form factor and ability to generate very long sequences from single DNA molecules. The platform is undergoing rapid evolution with three distinct nanopore types and five updates to library preparation chemistry in the last 18 months. To keep pace with the rapid evolution of this sequencing platform, and to provide a space where new analysis methods can be openly discussed, we present a new F1000Research channel devoted to updates to and analysis of nanopore sequence data.

Keywords
nanopore , MinION , sequencing , Oxford nanopore technology , MinION access programme , MinION analysis consortium

This article is included in the Nanopore Analysis gateway.
Nanopores are tiny hollow proteins, typically embedded in a membrane. DNA and RNA may be sequenced by monitoring electrical current changes as molecules block the nanopore and disrupt the flow of ions. These ideas have been explored and tinkered with in academic labs over 25 years. Recently, even the possibility of protein detection and characterisation has been proposed. But until recently nanopore sequencing has not made it into the hands of users. The first promises of a genuine sequencing product came at the Advances in Genome Biology and Technology (AGBT) 2012 in the form of an announcement from Oxford Nanopore Technologies. Attendees and observers were blown away by what was on offer: 100 kilobase long reads sequenced directly from blood, delivered in real-time. Perhaps most tantalisingly, this would be packaged up in a convenient USB stick sized device called the MinION.

An agonising delay followed to get the product to market, with manufacturing difficulties and a tiff with previous investor Illumina being blamed. Yet in May 2014, the first nanopore sequencers reached the hands of testers as part of the MinION Access Programme (MAP), an early access scheme rather different from roll-outs of other technologies. To reach a wide audience, MAP took a democratic approach and gave instruments to hundreds of labs, catering to highly diverse research interests. For many, including us, the device worked out of the box and delivered data (albeit small amounts and initially at low accuracy) as early as June 2014. Since then, for the MAP participants it has been a white-knuckle ride. We have had three “pore” changes (R6, which was only around for about a month, R7 and the current version R7.3). This was coupled with six chemistry changes and a software update seemingly every few weeks. For some it has been too much change, but early access programmes are not for everyone.

This pace of change has also taxed the community’s ability to reflect updates to the technology via traditional scientific publishing routes. As a consequence, in order to stay current, significant numbers of nanopore publications have been made available as preprints, with MAP participants being particularly enthusiastic adopters of the bioRxiv preprint server (http://www.biorxiv.org). Later on they have been accepted as formal peer-reviewed publications. BioRxiv is an excellent place to deposit manuscripts, establishing priority and soliciting early input into papers - potentially catching issues with analysis and fostering community discussion. But the site is mainly a simple document archiving service, with most discussion occurring via social networking sites like Twitter.

The first manuscript to be published in the nanopore channel is an extensive dataset of *Escherichia coli* K-12 whole genome sequencing and analysis, the fruits of almost a year of analysis by the MARC. The consortium sequenced the same strain stock across five different laboratories on two continents, according to a strictly followed protocol including DNA extraction, shearing and library preparation. In so doing they have provided a snapshot of the repeatability of the instrument performance in different laboratories and provided deep technical details into all aspects of the sequencing protocol. The result is a huge corpus of nanopore data which will be of great value to those wishing to analyse and model signal, or “squiggle”, level information from the platform. They show evidence that the platform behaves very consistently between different labs. With this version of the platform (R7.3 pore, version 5 chemistry) the yields of high quality data from the instrument are becoming impressive, with up to several hundreds of megabases per run. Using the nanopore-optimised MarginAlign software they report impressive accuracy scores of 92–93% when considering the filtered, best quality two-direction “passing” data.

The MARC analysis is as close we have to a Hayne’s manual (https://en.wikipedia.org/wiki/Haynes_Manual) for nanopore sequencing on the MinION. This is not the last word in nanopore analysis, the platform has already seen a new chemistry update, and this paper has focused on a single bacterial species. In time, we hope that the *F1000Research* nanopore analysis channel will continue to provide snapshots of the technology as it evolves, and that this manuscript will be joined by many others to provide a definitive collection. We look forward to receiving your manuscripts.

**Author contributions**

NL wrote the first draft of the manuscript, HJ, ML and SS assisted in writing of the manuscript. All authors read and approved the final version of the manuscript.

**Competing interests**

NJL is a member of the Oxford Nanopore MinION Access Programme (MAP) and has received reimbursement of expenses to speak at a company meeting. NJL has ongoing research collaborations with Oxford Nanopore but does not receive financial compensation from them. ML, HJ and SS are all members of the MAP and declare no conflicts of interest.

**Grant information**

NJL is supported by a Medical Research Council Fellowship in Microbial Bioinformatics as part of the Cloud Infrastructure for Microbial Bioinformatics (CLIMB) project. ML is supported by a TDRF award from the BBSC (BB/M020061/1) to develop tools for MinION sequencing.

**Acknowledgments**

The authors would like to thank Michael Markie at *F1000Research* for help and advice in preparing this manuscript and nanopore channel.
References


Comments on this article

Version 1

Reader Comment 15 Oct 2015

Torsten Seemann, The University of Melbourne, Australia

The initials of the authors are used incorrectly and inconsistently. "Sarah Goodwin" is labelled as "SS" and should be "SG". "Nick Loman" is "NJL" not "NL" which is minor but should be corrected.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com